New stroke drug shows promise in helping patients regain independence
NCT ID NCT07396337
First seen Feb 17, 2026 · Last updated May 22, 2026 · Updated 15 times
Summary
This study tests an investigational drug called QHRD106 for people who have had an acute ischemic stroke. The goal is to see if it can improve recovery and reduce disability when given within 24 hours of stroke onset. About 320 adults aged 18 to 80 who have not received standard clot-busting treatment will participate. The trial is double-blind and placebo-controlled, meaning some participants will receive the drug and others a placebo, with neither they nor their doctors knowing which.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, Jiangsu, 210008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.